LEADERS FREE: BioFreedom DCS vs. BMS in High-Bleeding Risk PCI Patients
The BioFreedom drug-coated stent demonstrated superiority to bare metal stents in patients undergoing percutaneous coronary intervention (PCI) with a high risk of bleeding, according to the results of the LEADERS FREE trial, presented Oct. 14 at TCT 2015 and simultaneously published in the New England Journal of Medicine.
In a prospective, double-blind randomized trial, Philip M. Urban, MD, FACC, et al., tested the efficacy and noninferiority of the BioFreedom drug-coated stent compared to the Gazelle bare-metal stent in 2466 high-bleeding risk PCI patients, with one month of dual antiplatelet therapy only. The primary safety endpoint was a composite of cardiac death, myocardial infarction and stent thrombosis at one year, while the efficacy endpoint was clinically-driven target lesion revascularization.
The results of the study showed that the BioFreedom drug-coated stent was both safer and more effective than a bare metal stent in PCI patients with a high risk of bleeding.
“Patients who have a high risk of bleeding during PCI are often excluded from stent and drug trials but constitute a rapidly growing proportion of PCI candidates and they suffer high event rates,” says Urban. The LEADERS FREE trial clearly showed the benefit of the BioFreedom drug-coated stent in this subset of patients, he continues.
< Back to Listings